Influence of gut microbiome on Tamoxifen metabolism
- Conditions
- C50Malignant neoplasm of breast
- Registration Number
- DRKS00029694
- Lead Sponsor
- Robert Bosch Gesellschaft für medizinische Forschung mbH (RBMF)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 37
Inclusion Criteria
Present, signed Informed Consent Form for the Establishment of a Biomaterial Bank in the TAMENDOX Study.
- continuing tamoxifen therapy (20 mg per day)
- completed 18th year of age
- ability to give consent
Exclusion Criteria
- lack of informed consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Plasma concentration of tamoxifen and metabolites<br>- Concentration of tamoxifen and metabolites in stool sample<br>- Composition of the bacterial population in the stool sample
- Secondary Outcome Measures
Name Time Method